Thermo Fisher Scientific INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Dion J Weisler, a Director of Thermo Fisher Scientific Inc., received 56 shares of common stock on September 26, 2026.
NYSE
Scott M Sperling, a Director of Thermo Fisher Scientific Inc., received 63 shares of common stock on September 26, 2026.
NYSE
Karen S Lynch, a Director of Thermo Fisher Scientific Inc., received 46 shares of common stock on September 26, 2026.
NYSE
R. Alexandra Keith, a Director of Thermo Fisher Scientific Inc., received 46 shares of common stock on September 26, 2026.
NYSE
Jennifer M Johnson, a Director of Thermo Fisher Scientific Inc., received 46 shares of common stock on September 26, 2026.
NYSE
James Meyer, Sr. Vice President & CFO of Thermo Fisher Scientific Inc., reported a transaction in 31 shares of common stock on August 22, 2026.
NYSE
Marc N Casper, Chairman & CEO and a Director of Thermo Fisher Scientific Inc., sold 20,000 shares of common stock on August 20, 2026.
NYSE
Lisa P. Britt, Sr. VP and Chief HR Officer of Thermo Fisher Scientific Inc., sold 11,440 shares of common stock on August 19, 2026 for $613.12 per share.
NYSE
Michael D Shafer, Executive Vice President of Thermo Fisher Scientific Inc., sold 25,500 shares of common stock on August 11, 2026 for $600.00 per share.
NYSE
Lisa P. Britt, Sr. VP and Chief HR Officer of Thermo Fisher Scientific Inc., sold 5,850 shares of common stock on August 6, 2026 for $580.00 per share.
NYSE
Marc N Casper, Chairman & CEO and a Director of Thermo Fisher Scientific Inc., sold 15,000 shares of common stock on August 6, 2026.
NYSE
Marc N Casper, Chairman & CEO and a Director of Thermo Fisher Scientific Inc., sold 15,000 shares of common stock on August 5, 2026.
NYSE
Gianluca Pettiti, President & COO of Thermo Fisher Scientific Inc., sold 400 shares of common stock on July 27, 2026 for $565.00 per share.
NYSE
Thermo Fisher Scientific Inc. reports a director, Scott M. Sperling, acquired stock units under the company's Deferred Compensation Plan for Directors.
NYSE
Thermo Fisher Scientific Inc. director Keith R. Alexandra acquired stock units under the company's Deferred Compensation Plan for Directors.
NYSE
Thermo Fisher Scientific Inc. director Dion J. Weisler acquired phantom stock units under the company's Deferred Compensation Plan for Directors.
NYSE
Thermo Fisher Scientific Director Karen S. Lynch acquired phantom stock units under the company's Deferred Compensation Plan for Directors.
NYSE
Jennifer M. Johnson, a Director at Thermo Fisher Scientific, acquired phantom stock units valued at $60.91 on June 27, 2026, under the company's Deferred Compensation Plan for Directors.
NYSE
Director Dion J. Weisler reported a net increase in his holdings of Thermo Fisher Scientific common stock following a tax-related disposition and a stock grant.
NYSE
Thermo Fisher Scientific director Scott M. Sperling acquired 499 shares of common stock as part of a compensation grant.
NYSE
Thermo Fisher Scientific director Debora L. Spar acquired 499 shares of common stock as part of a routine equity grant.
NYSE
Thermo Fisher Scientific director Karen S. Lynch acquired 499 shares of common stock as part of a routine equity grant.
NYSE
Thermo Fisher Scientific director R. Alexandra Keith acquired 499 shares of common stock as part of a compensation grant.
NYSE
Thermo Fisher Scientific director Jennifer M. Johnson acquired 499 shares of common stock as part of a routine equity grant.
NYSE
Thermo Fisher Scientific Director Tyler Jacks acquired 499 shares of common stock on May 20, 2026, increasing his direct beneficial ownership to 9,462 shares.
NYSE
Thermo Fisher Scientific director C. Martin Harris acquired 499 shares of common stock as part of a routine equity grant.
NYSE
Director Nelson Chai acquired 499 shares of Thermo Fisher Scientific Inc. common stock as part of a director compensation grant.
NYSE
Thermo Fisher Scientific Director Scott M. Sperling is scheduled to acquire 89.78 phantom stock units on March 28, 2026, through the company's deferred compensation plan.
NYSE
Thermo Fisher Scientific Director R. Alexandra Keith acquired 66.02 phantom stock units valued at $473.36 each under the company's deferred compensation plan.
NYSE
Thermo Fisher Scientific Director Karen S. Lynch acquired 66.02 phantom stock units through the company's deferred compensation plan.